FQHC 340B Audit Readiness: Documenting Compliance for HRSA and Manufacturer Audits

A 340B audit readiness guide for FQHCs: eligibility and OPAIS records, the patient definition, diversion and duplicate discount risks, Medicaid Exclusion File and managed care, contract pharmacy oversight, HRSA audit findings, manufacturer audits, the 2027 rebate pilot, and a self-audit plan.

KNOWLEDGE CENTER

11/15/202611 min read

The 340B Drug Pricing Program allows eligible covered entities, including health centers funded under Section 330 of the Public Health Service Act and FQHC look-alikes, to buy outpatient drugs at significantly reduced prices. For many health centers, 340B savings support services for low-income and uninsured patients. In exchange, covered entities must comply with strict program requirements and are subject to audits by HRSA and by drug manufacturers.

HRSA's Office of Pharmacy Affairs audits a sample of covered entities each year, publishes results, and requires corrective action plans and repayment to manufacturers when it finds noncompliance. Common findings include diversion of 340B drugs to ineligible patients, duplicate discounts involving Medicaid, and inaccurate records in the 340B Office of Pharmacy Affairs Information System (OPAIS). Manufacturers may also audit covered entities under HRSA guidelines.

The program environment is also changing. HRSA attempted to launch a 340B Rebate Model Pilot Program in January 2026, which a federal court enjoined, and then published a revised pilot that HRSA approved for certain drugs beginning January 1, 2027. This article explains 340B requirements for FQHCs, common audit findings, how to prepare for HRSA and manufacturer audits, and how to monitor changes. It is educational and does not replace legal or professional advice.

Core 340B Requirements

Eligibility

Health centers qualify for 340B based on their Section 330 grant or look-alike designation. They must register in OPAIS, register each site where 340B drugs will be used, and recertify annually. Sites must be in scope of the health center's HRSA project.

OPAIS Records

OPAIS records must be accurate and current, including the entity's name, address, authorizing official, primary contact, sites, shipping addresses, contract pharmacies, and Medicaid billing status. Inaccurate records are a frequent audit finding.

The Prohibition on Diversion

Section 340B(a)(5)(B) prohibits covered entities from reselling or otherwise transferring 340B drugs to a person who is not a patient of the entity. Diversion occurs when 340B drugs are dispensed or administered to ineligible individuals.

The Patient Definition

HRSA's 1996 guidance defines a patient of a covered entity. In general, an individual is a patient when:

• The covered entity has established a relationship with the individual, such that the covered entity maintains records of the individual's health care.

• The individual receives health care services from a health care professional who is employed by the entity or under contract or other arrangement, such that responsibility for the care remains with the entity.

• For health centers, the individual receives a range of services from the covered entity consistent with the services for which grant funding or look-alike designation has been provided.

An individual is not considered a patient if the only service received is the dispensing of a drug for self-administration or home use. Covered entities must apply the patient definition to every 340B prescription.

The Prohibition on Duplicate Discounts

Section 340B(a)(5)(A) prohibits duplicate discounts, which occur when a manufacturer gives a 340B discount and also pays a Medicaid drug rebate on the same drug. Covered entities manage this risk through the HRSA Medicaid Exclusion File for Medicaid fee-for-service and through state and managed care requirements for Medicaid managed care.

The Medicaid Exclusion File

Covered entities indicate in OPAIS whether they carve in, meaning they use 340B drugs for Medicaid fee-for-service patients and bill Medicaid, or carve out, meaning they do not use 340B drugs for Medicaid fee-for-service patients. Information must be listed by Medicaid billing number and National Provider Identifier. States use the file to exclude 340B claims from rebate requests. Billing practices must match the file.

Medicaid Managed Care

The Medicaid Exclusion File applies only to fee-for-service. For Medicaid managed care, states and plans use other methods, such as claim-level modifiers or identifiers, to prevent duplicate discounts. Covered entities must follow state requirements, which vary.

Contract Pharmacies

Covered entities may contract with outside pharmacies to dispense 340B drugs, subject to HRSA guidance, including written agreements, registration in OPAIS, and oversight. The covered entity remains responsible for compliance at contract pharmacies. HRSA's contract pharmacy guidance expects covered entities to conduct annual independent audits of contract pharmacy arrangements. Many manufacturers restrict 340B pricing at contract pharmacies, and litigation and state laws affect these policies.

HRSA Audits

How HRSA Selects and Conducts Audits

HRSA audits covered entities based on risk and also conducts targeted audits. Audits typically include a data request, a review of policies and procedures, a review of OPAIS records, and testing of a sample of 340B prescriptions or administrations at the entity and contract pharmacies.

Common HRSA Findings

HRSA's published audit results show recurring findings across covered entity types, including:

• Diversion, such as 340B drugs dispensed for prescriptions written at ineligible sites, dispensed to non-patients at contract pharmacies, or not supported by a medical record.

• Duplicate discounts, such as billing Medicaid while not listed on the Medicaid Exclusion File, or inaccurate or incomplete information on the file.

• Incorrect OPAIS records, such as incorrect shipping addresses, unregistered sites, or contract pharmacies that should have been removed.

Consequences

When HRSA finds noncompliance, it requires a corrective action plan, and sanctions can include repayment to manufacturers. In serious cases, entities can be removed from the program. HRSA publishes audit results, including findings and sanctions, on its program integrity web pages.

Corrective Action Plans

Corrective action plans must address each finding, describe root causes, and explain how the entity will prevent recurrence. They often include policy revisions, staff training, OPAIS corrections, contract pharmacy oversight, self-audits, and outreach to manufacturers for repayment.

Manufacturer Audits

HRSA Guidelines

Under Section 340B(a)(5)(C) and HRSA's 1996 manufacturer audit guidelines, manufacturers may audit covered entities if they have documentation indicating reasonable cause to believe a violation occurred. Manufacturers must first attempt in good faith to resolve the issue with the covered entity, must submit an audit work plan to HRSA for review, and must use an independent auditor. The covered entity must cooperate.

Dispute Resolution

HRSA's administrative dispute resolution process under 42 CFR Part 10 allows covered entities and manufacturers to bring certain claims, such as overcharges or diversion and duplicate discount claims after a manufacturer audit, before a panel.

Preparing for a Manufacturer Audit

• Review the audit scope and the HRSA-approved work plan.

• Assign a coordinator and involve counsel as appropriate.

• Provide documentation limited to the scope.

• Protect patient privacy consistent with HIPAA.

• Review findings carefully and respond with supporting documentation.

Developments in 2026 and 2027

The Rebate Model Pilot

In 2025, HRSA announced a 340B Rebate Model Pilot Program for certain drugs subject to Medicare drug price negotiation, under which covered entities would pay a higher price and receive rebates later. A federal district court in Maine enjoined the pilot before its planned January 1, 2026, start, and HHS later withdrew the initial version. In August 2026, HRSA published a revised pilot, and in October 2026, HRSA approved plans for certain manufacturers and drugs to participate beginning January 1, 2027. The revised pilot has also faced legal and legislative challenges. Health centers should monitor HRSA's 340B rebate pilot page and prepare for possible changes in purchasing, data submission, and cash flow for affected drugs.

Data Submission Pressure

Separate from the pilot, many manufacturers require covered entities to submit claims data through third-party platforms as a condition of receiving 340B pricing at contract pharmacies. Health centers should evaluate these requests with counsel, consider data privacy, and document decisions.

FQHC-Specific Considerations

Scope of Project

Only sites and services within the health center's HRSA scope of project are eligible. Sites must be listed on Form 5B and registered in OPAIS before 340B drugs are used there.

Referrals and Prescriptions From Outside Providers

Prescriptions written by outside providers are eligible only when the patient definition is met, such as when the health center maintains responsibility for the patient's care through a documented referral arrangement and receives the consult record. Health centers should define these situations in policy and retain documentation.

In-House Pharmacies and Medication Dispensing

Health centers with in-house pharmacies should maintain separate inventory or a compliant virtual inventory system, accurate accumulators, and records linking each dispense to an eligible patient and prescription.

Use of Savings

The 340B statute does not dictate how savings must be used, but health centers must use program income consistent with Health Center Program requirements. Documenting how 340B revenue supports the health center's mission is good practice and supports board oversight.

Building a 340B Compliance Program

Governance

• Designate a 340B program manager and oversight committee.

• Obtain board awareness of 340B participation and risks.

• Maintain written policies and procedures covering eligibility, patient definition, inventory, contract pharmacies, Medicaid, and self-audits.

OPAIS Management

• Review OPAIS records quarterly and after any change in sites, contacts, or contract pharmacies.

• Complete annual recertification on time.

• Keep the Medicaid Exclusion File accurate by NPI and Medicaid number.

Self-Audits

• Audit a sample of 340B dispenses and administrations monthly or quarterly, at the entity and each contract pharmacy.

• Test patient eligibility, prescriber eligibility, site eligibility, and documentation.

• Test Medicaid billing against the exclusion file and state managed care rules.

• Reconcile purchases and dispenses.

Contract Pharmacy Oversight

• Maintain written agreements.

• Review third-party administrator reports regularly.

• Conduct annual independent audits of contract pharmacy arrangements.

Training

• Train providers, pharmacy staff, and billing staff on 340B requirements.

• Update training when policies or rules change.

Self-Disclosure

• When material noncompliance is identified, evaluate self-disclosure to HRSA and manufacturers, repay as required, and document corrective actions.

Audit Readiness Checklist

• Current policies and procedures, with approval dates.

• OPAIS records printed or saved, with verification that they are accurate.

• Medicaid Exclusion File entries and supporting billing documentation.

• Lists of sites, providers, and contract pharmacies.

• Contract pharmacy agreements and audit reports.

• Self-audit results and corrective actions.

• Purchasing and dispensing records.

• Training records.

• Prior HRSA or manufacturer audit results and corrective action plans.

A Hypothetical Example

A health center's self-audit finds that a contract pharmacy dispensed 340B drugs for prescriptions written by a specialist who had no documented referral relationship with the health center, and that a newly opened site was not yet registered in OPAIS. The health center updates its referral policy, corrects its third-party administrator settings to exclude ineligible prescribers, registers the site, repays affected manufacturers, and documents the corrective actions. When HRSA selects the health center for audit the following year, auditors find no adverse findings.

Inventory Management

Covered entities must be able to show that 340B drugs were used only for eligible patients. Two inventory approaches are common. A physical inventory keeps 340B drugs separate from non-340B drugs. A virtual or replenishment inventory uses a shared stock, with software that tracks eligible dispenses and accumulates units to trigger 340B replenishment orders. Under either model, health centers should be able to trace each 340B purchase to eligible use. Common inventory issues include accumulator errors, incorrect National Drug Code mapping, package size mismatches, and replenishment based on ineligible dispenses. Monthly reconciliation of purchases, accumulations, and dispenses helps catch errors early.

Group Purchasing Organization Prohibition

The 340B statute's group purchasing organization prohibition applies to certain hospital covered entities, not to health centers. However, health centers should still ensure that drugs purchased at 340B prices are used only for eligible outpatient use and are not mixed with other purchasing accounts in ways that create diversion.

Working With Third-Party Administrators

Most health centers with contract pharmacies use third-party administrators to determine eligibility and manage replenishment. The health center, not the administrator, is responsible for compliance. Health centers should:

• Review and approve the eligibility logic, including eligible sites, prescribers, and encounter look-back periods.

• Provide accurate prescriber and site lists and update them promptly.

• Review exception and exclusion reports.

• Audit a sample of claims qualified by the administrator.

• Confirm Medicaid claims are excluded or handled according to the health center's Medicaid status and state requirements.

Common Myths About 340B

Myth: Any Prescription From a Health Center Provider Is Eligible

Eligibility depends on the patient definition, site eligibility, and the drug being for outpatient use.

Myth: The Third-Party Administrator Guarantees Compliance

The covered entity remains responsible.

Myth: The Medicaid Exclusion File Covers Managed Care

It applies to fee-for-service. Managed care duplicate discount prevention depends on state rules.

Myth: Health Centers Are Rarely Audited

HRSA audits all types of covered entities, and manufacturers can audit with HRSA approval.

Questions Leadership Should Ask

• When were our OPAIS records last verified?

• Is our Medicaid Exclusion File accurate and consistent with billing?

• How do we prevent duplicate discounts in Medicaid managed care?

• How often do we self-audit at each contract pharmacy?

• Have we completed annual independent audits of contract pharmacy arrangements?

• How will the 2027 rebate pilot affect our purchasing and cash flow?

Key Takeaways

• 340B compliance rests on eligibility, accurate OPAIS records, the patient definition, and preventing diversion and duplicate discounts.

• HRSA's common findings involve diversion, Medicaid duplicate discounts, and incorrect OPAIS records.

• Manufacturers may audit under HRSA guidelines after good faith resolution efforts.

• The revised rebate pilot is scheduled to begin January 1, 2027, for certain drugs.

• Regular self-audits, contract pharmacy oversight, and training reduce risk.

Documenting Referral Relationships

Prescriptions written by outside specialists are a frequent source of diversion findings. HRSA's patient definition requires that responsibility for care remain with the covered entity. Health centers that count prescriptions from referral providers as eligible should document the referral, receive and review the consult note, and maintain the patient's ongoing care relationship with the health center. Written policies should define when outside prescriptions qualify, and third-party administrator settings should match the policy. Self-audits should specifically test outside prescriptions.

Board and Leadership Oversight

340B compliance is an organizational responsibility. Boards should receive periodic reports on 340B participation, savings, self-audit results, and corrective actions, and leadership should ensure adequate staffing and resources for compliance. Documenting this oversight demonstrates a culture of compliance and supports the health center in audits.

Responding to an HRSA Audit Notice

When HRSA notifies a health center of an audit, the health center typically receives a data request with a deadline. Steps include:

• Designate a coordinator and notify leadership.

• Review the request and confirm the audit period.

• Gather policies, OPAIS records, contract pharmacy information, and purchase and dispense data.

• Run an internal review of the sample period before submitting data.

• Prepare staff for interviews.

• Respond accurately and on time.

After the audit, review the preliminary findings carefully. Covered entities typically have an opportunity to respond to findings before they are finalized, so provide documentation that addresses any errors. If findings are finalized, submit a corrective action plan within the required time frame.

Preparing for Medicaid Changes

Medicaid policies affecting 340B change frequently. States may change carve-in or carve-out requirements, modifiers, reimbursement for 340B drugs, and managed care rules. Health centers should monitor state notices, update the Medicaid Exclusion File and billing practices when policies change, and document the effective dates of changes. Many duplicate discount findings result from changes that were not reflected promptly in billing or HRSA records.

Documentation Retention

Health centers should retain 340B records, including purchase records, dispensing records, eligibility determinations, policies, and audit results, for the period required by HRSA guidance and applicable law, commonly at least five years. Organized records make audits faster and reduce the risk of findings based on missing documentation.

Measuring Program Health

Track key indicators each quarter: self-audit error rates, OPAIS update timeliness, contract pharmacy exception rates, Medicaid billing accuracy, and corrective action status. Report results to the compliance committee and board. Trends help leaders spot problems before an audit does and show auditors that the health center monitors its program actively.

Frequently Asked Questions

What are the most common HRSA 340B audit findings?

Diversion to ineligible patients or sites, duplicate discounts involving Medicaid, and inaccurate OPAIS records.

Who is a 340B patient?

Generally, an individual for whom the covered entity maintains health records and provides care through its professionals, consistent with the scope of its grant or designation, and not someone who receives only a prescription.

What is the Medicaid Exclusion File?

An HRSA file showing whether a covered entity uses 340B drugs for Medicaid fee-for-service patients, used by states to prevent duplicate discounts.

Can manufacturers audit FQHCs?

Yes, under HRSA guidelines, after attempting good faith resolution and submitting an audit work plan to HRSA.

Will the 340B rebate pilot affect FQHCs?

The revised pilot applies to certain drugs and manufacturers approved by HRSA beginning January 1, 2027, subject to legal and legislative developments.

Conclusion

340B savings are vital to many health centers, but they depend on strict compliance. FQHCs that maintain accurate OPAIS records, apply the patient definition consistently, prevent duplicate discounts, oversee contract pharmacies, conduct regular self-audits, and monitor program changes will be prepared for HRSA and manufacturer audits.

How HealthBridge Can Help

HealthBridge is a healthcare management consulting firm that helps health centers assess 340B compliance, update policies, review OPAIS and Medicaid Exclusion File records, conduct self-audits and contract pharmacy reviews, prepare for HRSA and manufacturer audits, and develop corrective action plans. If your health center wants to strengthen its 340B program, please get in touch with us. We will be happy to help you with this topic.

References

• U.S. Code. 42 U.S.C. 256b, Limitation on Prices of Drugs Purchased by Covered Entities (Section 340B of the Public Health Service Act). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section256b&num=0&edition=prelim

• Health Resources and Services Administration, Office of Pharmacy Affairs. 340B Drug Pricing Program. https://www.hrsa.gov/opa

• Health Resources and Services Administration, Office of Pharmacy Affairs. Program Integrity. https://www.hrsa.gov/opa/program-integrity

• Health Resources and Services Administration, Office of Pharmacy Affairs. Program Integrity: FY 25 Audit Results. https://hrsa.gov/opa/program-integrity/fy-25-audit-results

• Health Resources and Services Administration, Office of Pharmacy Affairs. 340B Rebate Model Pilot Program. https://www.hrsa.gov/opa/340b-model-pilot-program

• Federal Register. Notice Regarding Section 602 of the Veterans Health Care Act of 1992; Patient and Entity Eligibility (61 FR 55156, October 24, 1996). https://www.govinfo.gov/content/pkg/FR-1996-10-24/pdf/96-27344.pdf

• Federal Register. Manufacturer Audit Guidelines and Dispute Resolution Process (61 FR 65406, December 12, 1996). https://www.govinfo.gov/content/pkg/FR-1996-12-12/pdf/96-31375.pdf

• Federal Register. Notice Regarding 340B Drug Pricing Program; Contract Pharmacy Services (75 FR 10272, March 5, 2010). https://www.govinfo.gov/content/pkg/FR-2010-03-05/pdf/2010-4755.pdf

• Electronic Code of Federal Regulations. 42 CFR Part 10, 340B Drug Pricing Program. https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-10

• U.S. Government Accountability Office. Drug Pricing Program: HHS Uses Multiple Mechanisms to Help Ensure Compliance with 340B Requirements (GAO-21-107). https://www.gao.gov/assets/720/711409.pdf

• Health Resources and Services Administration, Bureau of Primary Health Care. Scope of Project. https://bphc.hrsa.gov/compliance/scope-project

Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources